PDCD1 and neoplasm: Immune checkpoint inhibitors (ICIs), represented by inhibitors of PD‐1 and its ligand PD‐L1, have achieved breakthrough progress in tumor immunotherapy, particularly in the treatment of lung cancer, renal cancer, and melanoma.4